The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β

mAbs

Volumn 7, Issue 6, 2015, Pages 1151-1160

  Rondeau, Jean Michel ^a   Ramage, Paul ^a   Zurini, Mauro ^a   Gram, Hermann ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Canakinumab; Cryopyrin associated periodic syndrome; Crystal structure; Gouty arthritis; Interleukin 1 ; Mode of action; Species specificity; Systemic juvenile idiopathic arthritis; Therapeutic antibody

Indexed keywords

BACTERIAL VECTOR; CANAKINUMAB; COMPLEMENTARY DNA; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; GLUTAMIC ACID; INTERLEUKIN 1 RECEPTOR; PROTEIN BINDING;

ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALLITRICHINAE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CROSS REACTIVITY; DRUG DETERMINATION; DRUG PROTEIN BINDING; ESCHERICHIA COLI; FIBROBLAST CULTURE; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC50; IMMUNOGLOBULIN VARIABLE REGION; MACACA FASCICULARIS; MUTATIONAL ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN PURIFICATION; RABBIT; SURFACE PLASMON RESONANCE; WESTERN BLOTTING; X RAY ANALYSIS; ANIMAL; BINDING COMPETITION; CALLITHRIX; CHEMICAL STRUCTURE; CHEMISTRY; CROSS REACTION; IMMUNOLOGY; MACACA; METABOLISM; MOUSE; PROTEIN TERTIARY STRUCTURE; RAT; SPECIES DIFFERENCE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; BINDING, COMPETITIVE; CALLITHRIX; CROSS REACTIONS; CRYSTALLOGRAPHY, X-RAY; EPITOPES; GLUTAMIC ACID; HUMANS; INTERLEUKIN-1BETA; MACACA; MICE; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RABBITS; RATS; RECEPTORS, INTERLEUKIN-1; SPECIES SPECIFICITY;

EID: 84951197004     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1081323     Document Type: Article

References (32)

1. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27:519-50; PMID:19302047; http://dx. doi. org/ 10. 1146/annurev. immunol. 021908. 132612
2. Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discovery 2012; 11:633-52; PMID:22850787; http://dx. doi. org/ 10. 1038/nrd3800
3. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunology 2010; 10:89-102; PMID:20081871; http://dx. doi. org/10. 1038/ nri2691
4. Sims JE, Smith DE. Regulation of interleukin-1 activity is enhanced by cooperation between the interleukin-1 receptor type II and interleukin-1 receptor accessory protein. Eur Cytokine Netw 2003; 14:77-81; PMID:12957787
5. Priestle JP, Schär HP, Grütter MG. Crystallographic refinement of interleukin 1 beta at 2. 0 A resolution. Proc Natl Acad Sci U S A 1989; 86:9667-71; PMID:2602367; http://dx. doi. org/10. 1073/ pnas. 86. 24. 9667
6. Schreuder HA, Rondeau JM, Tardif C, Soffientini A, Sarubbi E, Akeson A, Bowlin TL, Yanofsky S, Barrett RW. Refined crystal structure of the interleukin-1 receptor antagonist. Presence of a disulfide link and a cis-proline. Eur J Biochem 1995; 227:838-47; PMID:7867645; http://dx. doi. org/10. 1111/j. 1432-1033. 1995. tb20209. x
7. Vigers GP, Anderson LJ, Caffes P, Brandhuber BJ. Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta. Nature 1997; 386:190-4; PMID:9062193; http://dx. doi. org/ 10. 1038/386190a0
8. Thomas C, Bazan JF, Garcia KC. Structure of the activating IL-1 receptor signaling complex. Nat Struct Mol Biol 2012; 19:455-7; PMID:22426547; http://dx. doi. org/10. 1038/nsmb. 2260
9. Wang D, Zhang S, Li L, Liu X, Mei K, Wang X. Structural insights into the assembly and activation of IL-1β with its receptors. Nat Immunology 2010; 11:905-11; http://dx. doi. org/10. 1038/ ni. 1925
10. Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, Burmester G, van Riel P, Diaz-Lorente M, Bruin GJM, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10:R67; PMID:18534016; http://dx. doi. org/10. 1186/ar2438
11. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360:2416-25; PMID:19494217; http://dx. doi. org/10. 1056/NEJMoa0810787
12. RupertoN, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367:2396-406; PMID:23252526; http://dx. doi. org/10. 1056/NEJMoa1205099
13. Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, Krammer G, Murphy V, Richard D, So AK. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, activecontrolled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71:1839-48; PMID:22586173; http://dx. doi. org/10. 1136/ annrheumdis-2011-200908
14. Blech M, Peter D, Fischer P, Bauer MMT, Hafner M, Zeeb M, Nar H. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β. J Mol Biol 2013; 425:94-111; PMID:23041424; http://dx. doi. org/10. 1016/j. jmb. 2012. 09. 021
15. Lefranc MP. Nomenclature of the human immunoglobulin kappa (IGK) genes. Exp Clin Immunogenet 2001; 18:161-74; PMID:11549845; http://dx. doi. org/ 10. 1159/000049195
16. Pallarès N, Lefebvre S, Contet V, Matsuda F, Lefranc MP. The human immunoglobulin heavy variable genes. Exp Clin Immunogenet 1999; 16:36-60; PMID:Can't; http://dx. doi. org/10. 1159/ 000019095
17. Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 1997; 273:927-48; PMID:9367782; http://dx. doi. org/10. 1006/ jmbi. 1997. 1354
18. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest, 5th edit., NIH Publication no. 91-3242. Washington DC: US Department of Health and Human Services; 1991.
19. Morea V, Tramontano A, Rustici M, Chothia C, Lesk AM. Conformations of the third hypervariable region in the VH domain of immunoglobulins. J Mol Biol 1998; 275:269-94; PMID:9466909; http://dx. doi. org/ 10. 1006/jmbi. 1997. 1442
20. Lawrence MC, Colman PM. Shape complementarity at protein-protein interfaces. J Mol Biol 1993; 234:946-50; PMID:8263940; http://dx. doi. org/10. 1006/ jmbi. 1993. 1648
21. Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC. Structural insights into the evolution of an antibody combining site. Science 1997; 276:1665-9; PMID:9180069; http://dx. doi. org/10. 1126/ science. 276. 5319. 1665
22. Lo Conte L, Janin J, Chothia C. The structure of protein-protein recognition sites. J Biol Chem 1990; 265:16027-30; PMID:2204619
23. Bhat TN, Bentley GA, Boulot G, Greene MI, Tello D, Dall'Acqua W, Souchon H, Schwarz FP, Mariuzza RA, Poljak RJ. Bound water molecules and conformational stabilization help mediate an antigen-antibody association. Proc Natl Acad Sci U S A 1994; 91:1089-93; PMID:8302837; http://dx. doi. org/10. 1073/ pnas. 91. 3. 1089
24. Van Oostrum J, Priestle JP, GrutterMG, Schmitz A. The structure of murine interleukin-1beta at 2. 8 Å resolution. J Struct Biol 1991; 107:189-95; PMID:1807351; http:// dx. doi. org/10. 1016/1047-8477(91)90021-N
25. Ohlendorf DH, Treharne AC, Weber PC, Wendoloski JJ, Salemme FR. A comparison of the high resolution structures of human and murine interleukin-1beta. RCSB PDB 1992; entry 8I1B; http://www. ncbi. nlm. nih. gov/Structure/mmdb/mmdbsrv. cgi?uid=58606
26. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallogr Sect A Found Crystallogr 1994; 50:157-63; http://dx. doi. org/10. 1107/ S0108767393007597
27. Brünger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998; 54:905-21; PMID:9757107; http://dx. doi. org/ 10. 1107/S0907444998003254
28. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr Sect A Found Crystallogr 1991; 47: 110-9; http://dx. doi. org/10. 1107/ S0108767390010224
29. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzym 1997; 276:307-26; http://dx. doi. org/10. 1016/ S0076-6879(97)76066-X
30. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr 2007; 40:658-74; PMID:19461840; http://dx. doi. org/10. 1107/ S0021889807021206
31. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr Sect D Biol Crystallogr 2010; 66:486-501; http://dx. doi. org/ 10. 1107/S0907444910007493
32. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AGW, McCoy A, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. Sect. D Biol. Crystallogr. 2011; 67:235-42; http://dx. doi. org/ 10. 1107/S0907444910045749